Skip to content
OpenCapital
Get started

Twist Bioscience Corporation TWST Reportable Segment — Stock-based compensation expense

Similar metrics at other companies

Dolby Laboratories, Inc. logo
DLBReportable Segment — Stock-based compensation expense
$30.71M+0.1%
Hinge Health, Inc. logo
HNGEReportable Segment — Stock-based compensation expense
$11.69M+166,929%
Enphase Energy logo
ENPHReportable Segment — Stock-based compensation expense
$48.99M-11.9%
WillScot Holdings Corporation logo
WSCReportable Segment — Stock compensation expense
$7.11M-14.8%
Synaptics logo
SYNAReportable Segment — Stock-Based Comp
$300K0.0%
Mirum Pharmaceuticals, Inc. logo
MIRMReportable Segment — Stock-Based Comp
$57.13M+269%

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$5.45B+24.4%

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Twist Bioscience Corporation's reportable segment — stock-based compensation expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Twist Bioscience Corporation's reportable segment — stock-based compensation expense?
Twist Bioscience Corporation (TWST) reported reportable segment — stock-based compensation expense of $18.94M in Q1 2026.
How has Twist Bioscience Corporation's reportable segment — stock-based compensation expense changed year-over-year?
Twist Bioscience Corporation's reportable segment — stock-based compensation expense decreased by 6.8% year-over-year, from $20.33M to $18.94M.
What does reportable segment — stock-based compensation expense mean?
Measures the non-cash expense recognized for equity-based awards granted to employees and management within the reportable segment. It is a key indicator of talent retention costs and the dilution impact on existing shareholders.